News
ABOUT US
NAMPA UNIVERSE
PARTNERS
Windhoek, 26 February - Commissioner of the Namibia Revenue Agency, Sam Shivute at the tabling of the 2026/27 Appropriation Bill. (Photo by Eba Kandovazu). NAMPA
Windhoek, 26 February- Prime Minister Elijah Ngurare at the tabling of the 2026/27 Appropriation Bill. (Photo by Eba Kandovazu). NAMPA
Windhoek, 26 February- Minister of Education, Innovation, Sports, Arts and Culture, Sanet Steenkamp. (Photo by Eba Kandovazu). NAMPA
Windhoek, 26 February- President of the Popular Democratic Movement, McHenry Venaani. (Photo by Eba Kandovazu). NAMPA
Windhoek, 26 February- Minister of Information, Communication and Technology. (Photo by Eba Kandovazu). NAMPA
Windhoek, 26 February- Minister of Information, Communication and Technology, Emma Theofelus. (Photo by Eba Kandovazu). NAMPA
Windhoek, 26 February- Minister of Finance, Ericah Shafuda at the tabling of the 2026/27 Appropriation Bill. (Photo by Eba Kandovazu). NAMPA
Windhoek, 26 February- Minister of Finance, Ericah Shafudaat the tabling of the 2026/27 Appropriation Bill. (Photo by Eba Kandovazu). NAMPA
Protestors react and hold portraits of Reza Pahlavi II during a demonstration organised by members of the Iranian diaspora outside the United Nations offices during new round of talks between the United States and Iran on Iran’s nuclear program, in Geneva on February 26, 2026. (Photo by Fabrice COFFRINI / AFP)
South Africa's Quinton de Kock plays a shot during the 2026 ICC Men's T20 Cricket World Cup Super Eights match between West Indies and South Africa at Narendra Modi Stadium in Ahmedabad on February 26, 2026. (Photo by Shammi MEHRA / AFP)
Spectators watch the 2026 ICC Men's T20 Cricket World Cup Super Eights match between West Indies and South Africa at Narendra Modi Stadium in Ahmedabad on February 26, 2026. (Photo by Shammi MEHRA / AFP)
A clinician administers a dose of the long-acting injectable HIV pre-exposure prophylaxis (PrEP), Lenacapavir injection to a client, during its launch marking the first phase of the national rollout at the Riruta Health Centre in Nairobi on February 26, 2026. Kenya began administering the first dose of a groundbreaking HIV prevention drug in a Nairobi slum on Thursday. Lenacapavir, taken twice a year, has been shown to reduce the risk of HIV transmission by more than 99.9 percent, though it is technically a chemical drug rather than a vaccine because it does not train the immune system. (Photo by SIMON MAINA / AFP)
A clinician administers a dose of the long-acting injectable HIV pre-exposure prophylaxis (PrEP), Lenacapavir injection to a client, during its launch marking the first phase of the national rollout at the Riruta Health Centre in Nairobi on February 26, 2026. Kenya began administering the first dose of a groundbreaking HIV prevention drug in a Nairobi slum on Thursday. Lenacapavir, taken twice a year, has been shown to reduce the risk of HIV transmission by more than 99.9 percent, though it is technically a chemical drug rather than a vaccine because it does not train the immune system. (Photo by SIMON MAINA / AFP)
A clinician fill a syringe a dose of the long-acting injectable HIV pre-exposure prophylaxis (PrEP), Lenacapavir injection before administering to a client, during its launch marking the first phase of the national rollout at the Riruta Health Centre in Nairobi on February 26, 2026. Kenya began administering the first dose of a groundbreaking HIV prevention drug in a Nairobi slum on Thursday. Lenacapavir, taken twice a year, has been shown to reduce the risk of HIV transmission by more than 99.9 percent, though it is technically a chemical drug rather than a vaccine because it does not train the immune system. (Photo by SIMON MAINA / AFP)
A clinician fill a syringe a dose of the long-acting injectable HIV pre-exposure prophylaxis (PrEP), Lenacapavir injection before administering to a client, during its launch marking the first phase of the national rollout at the Riruta Health Centre in Nairobi on February 26, 2026. Kenya began administering the first dose of a groundbreaking HIV prevention drug in a Nairobi slum on Thursday. Lenacapavir, taken twice a year, has been shown to reduce the risk of HIV transmission by more than 99.9 percent, though it is technically a chemical drug rather than a vaccine because it does not train the immune system. (Photo by SIMON MAINA / AFP)
Peace Lawrence 23, holds a dose of the long-acting injectable HIV pre-exposure prophylaxis (PrEP), Lenacapavir tablets, during its launch marking the first phase of the national rollout at the Riruta Health Centre in Nairobi on February 26, 2026. Kenya began administering the first dose of a groundbreaking HIV prevention drug in a Nairobi slum on Thursday. Lenacapavir, taken twice a year, has been shown to reduce the risk of HIV transmission by more than 99.9 percent, though it is technically a chemical drug rather than a vaccine because it does not train the immune system. (Photo by SIMON MAINA / AFP)
